DIAGNOSTIC RADIOISOTOPES MARKET ANALYSIS

Diagnostic Radioisotopes Market, By Radioisotope (Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, Others ), By Application (Diagnostic Application and Therapeutic Application), By Imaging Modality (SPECT, PET, Beta Emitters), By Disease Indication (Oncology, Cardiology, Neurology, Thyroid, Orthopedic, Endocrinology, Others), By End User (Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global Diagnostic Radioisotopes Market- Regional Insights

North America is expected to be the largest market for diagnostic radioisotopes during the forecast period, accounting for over 41.5% of the market share in 2023. The growth of the market in North America is attributed to the high healthcare expenditure and developed healthcare infrastructure.
Europe is expected to be the second-largest market for diagnostic radioisotopes, accounting for over 28.2% of the market share in 2023. The growth of the market in is attributed to the rising cancer cases and product launches.
Asia Pacific is expected to be the fastest-growing market for diagnostic radioisotopes, with a CAGR of over 22.6% during the forecast period. The growth of the market in Asia Pacific is attributed to the large patient pool and increasing awareness.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East & Africa: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa